BRIEF published on 04/07/2026 at 11:10, 21 days 2 hours ago Virbac: Declaration on voting rights as of March 31, 2026 Voting Rights Euronext Actions Finance VIRBAC
PRESS RELEASE published on 03/17/2026 at 19:00, 1 month 10 days ago Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025
BRIEF published on 12/16/2025 at 09:58, 4 months 12 days ago Virbac acquires Thyronorm for the treatment of feline hyperthyroidism Acquisition Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
BRIEF published on 12/16/2025 at 09:58, 4 months 12 days ago Virbac Acquires Thyronorm to Combat Feline Hyperthyroidism Veterinary Medicine Animal Health Feline Hyperthyroidism VIRBAC Thyronorm
PRESS RELEASE published on 12/16/2025 at 09:53, 4 months 12 days ago VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Virbac acquires innovative drug Thyronorm from Norbrook to stabilize feline hyperthyroidism, expanding distribution in key markets and enhancing senior cats' quality of life Acquisition Feline Hyperthyroidism VIRBAC Thyronorm Senior Cats
BRIEF published on 11/07/2025 at 15:44, 5 months 20 days ago Virbac: Update on shares and voting rights Euronext Paris Voting Rights Actions Transparency VIRBAC
BRIEF published on 09/12/2025 at 17:50, 7 months 15 days ago Virbac Reports Solid Growth in 2025 First Half Results Revenue Growth Operating Income VIRBAC 2025 Forecast Global Market Performance
PRESS RELEASE published on 09/12/2025 at 17:45, 7 months 15 days ago Virbac: 2025 Half-year results Virbac reports solid revenue growth of 5.6% in the first half of 2025, meeting adjusted operating income expectations. Targets for 2025 confirmed with revenue growth of 4-6% expected Financial Results Revenue Growth Operating Income VIRBAC Targets Confirmed
BRIEF published on 08/18/2025 at 09:35, 8 months 10 days ago Virbac reveals the remuneration of its new CEO General Manager Remuneration VIRBAC Free Shares Paul Martingell
PRESS RELEASE published on 08/18/2025 at 09:30, 8 months 10 days ago Virbac:: Paul Martingell's compensation terms Virbac's board of directors approves compensation terms for Paul Martingell as CEO, including fixed and variable components, long-term incentives, and exceptional benefits Board Of Directors CEO VIRBAC Paul Martingell Compensation Terms
Published on 04/28/2026 at 13:00, 12 minutes ago Meta Critical Minerals Signs Option Agreement To Acquire High-Grade U.S. Critical Minerals Project Covering Two Historical Deposits Rich in Zircon, Titanium and Rare Earths
Published on 04/28/2026 at 12:00, 1 hour 12 minutes ago Dynamite Deploys AI-Powered Identity Technology to Deliver Institutional-Grade Security at Consumer-Level Simplicity
Published on 04/28/2026 at 11:00, 2 hours 12 minutes ago Kingfisher Metals Confirms Early Jurassic Porphyry Mineralization Across Hank-Mary District, a Fertile Window Between Mitchell Cu-Au and Brucejack Au-Ag Deposits
Published on 04/28/2026 at 09:05, 4 hours 7 minutes ago BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
Published on 04/28/2026 at 09:01, 4 hours 11 minutes ago Star Copper Completes Copperline Project Inaugural 2025 Field Program at Omineca Mining Division, BC
Published on 04/28/2026 at 13:00, 12 minutes ago mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics
Published on 04/28/2026 at 12:30, 42 minutes ago Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Published on 04/28/2026 at 12:27, 44 minutes ago EQS-Adhoc: TIN INN Holding AG: TIN INN Holding AG enters into framework agreements with institutional investor for development of up to 20 hotel locations
Published on 04/28/2026 at 07:20, 5 hours 52 minutes ago Growth, Performance and Record Investments: Air Liquide continues on its successful trajectory in Q1 2026
Published on 04/27/2026 at 17:45, 19 hours 27 minutes ago Convocation annual general meeting of May 27, 2026
Published on 04/27/2026 at 17:35, 19 hours 37 minutes ago Disclosure of transactions in own shares from April 20 to April 24, 2026
Published on 04/27/2026 at 11:42, 1 day 1 hour ago Description of the share repurchase program authorized by the Combined General Meeting of the shareholders of April 24, 2026
